Lead Product(s): Dibuprenorphine-ethyl-ether
Therapeutic Area: Gastroenterology
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2020
The study is designed to assess safety and efficacy of ORP-101 compared to placebo and includes two pre-defined interim analyses, both of which are anticipated in the second half of 2020.